{"ticker": {"uuid": "88b6ea3a-394d-4870-9953-fd888263aaf9", "symbol": "SRPT", "name": "Sarepta Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "SRPT Stock Clocks Highest Daily Gain In Nearly 8 Years After Rare Muscle Disorders Study Data But Wall Street's Not Wholly Convinced", "summary": "Sarepta Therapeutics (SRPT) shares jumped 35% after releasing early clinical data for its rare muscle disorder programs, DM1 and FSHD1. While some analysts found the data promising, others expressed caution due to limitations in the data and safety concerns. The company's investi", "url": "https://stocktwits.com/news-articles/markets/equity/srpt-stock-clocks-highest-daily-gain-in-nearly-8-years-after-rare-muscle-disorders-study-data/cZ3pTn6RIjd", "source_name": "Stocktwits", "published_at": "2026-07-16T12:10:30", "published_display": "16 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trading Systems Reacting to (SRPT) Volatility", "summary": "This article from Stock Traders Daily discusses the volatility of Sarepta Therapeutics Inc. (NASDAQ: SRPT), highlighting conflicting sentiment across different time horizons. It provides AI-generated trading strategies including position trading, momentum breakout, and risk hedgi", "url": "https://news.stocktradersdaily.com/news_release/17/Trading_Systems_Reacting_to_SRPT_Volatility_071626014001_1784180401.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-16T01:40:32", "published_display": "16 Jul 2026 01:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Sarepta Therapeutics (SRPT) Undervalued Following FDA Progress On AMONDYS 45 And VYONDYS 53?", "summary": "Sarepta Therapeutics (SRPT) is being re-evaluated after the FDA accepted supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53, Duchenne muscular dystrophy therapies. While the stock has seen a recent 30-day rebound, its long-term shareholder returns remain negative. T", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/is-sarepta-therapeutics-srpt-undervalued-following-fda-progr", "source_name": "Simply Wall Street", "published_at": "2026-07-15T12:10:30", "published_display": "15 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Sarepta Therapeutics, Inc. (SRPT)", "summary": "Johnson Fistel, PLLP is investigating potential claims on behalf of long-term shareholders of Sarepta Therapeutics, Inc. (SRPT) who held shares continuously since before June 22, 2023. The investigation concerns alleged breaches of fiduciary duty by Sarepta's officers and directo", "url": "https://supplychaindigital.com/globenewswire/3326258", "source_name": "Supply Chain Digital", "published_at": "2026-07-14T08:11:46", "published_display": "14 Jul 2026 08:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Following FDA sNDA Acceptance Is Sarepta Therapeutics (SRPT) Still Undervalued?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPZldZR01LaFJWSjhqaEFTdi1tRzZISGpmajgyZlk4aEhfTmFQc0tpM2VlNnlYNVFDRl9xUW9CN1JmVG8zbEthbmR2NXZDM3R3dGJnWU0zZXQ2NTBMS1dOZHZmZkQ3WERIcGdEdC1oYUFOaTFPWHk1N1gtNV9FeWFvVW1IdmtjNEZiZ1o1dkFUazQ3eEc4R2M0UDRxcU5wQUU?oc=5", "source_name": "Market source", "published_at": "2026-07-14T01:10:00+00:00", "published_display": "14 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For Sarepta Therapeutics (SRPT) Could Change Following FDA sNDA Acceptance On DMD Therapies", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxObk51bU1mR3FzU2NEWnN0YnJqQkloRVVSMDR5aHZoNlJ2UHVqNGlZdWdIQ2MxNUh0bGM5LVp5dTA3ajEzQ2ZpczFoWkE4YjM4dDhsTWVtUzk0a2xGYnZMSWh1STVDLTljQWg0Sm1mSDJoUkhvR1RCVzcxUUJKOWkwZHhfd3hVZHdhNWVMMGU5THE1TlRNeXZwVjhtRWg?oc=5", "source_name": "Market source", "published_at": "2026-07-14T00:22:00+00:00", "published_display": "14 Jul 2026 00:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Sarepta Therapeutics (SRPT) Stock Analysis: Evaluating a 16.53% Potential Upside Amidst a Volatile Biotech Landscape", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxOUG1ibFpjUk42WE1FblNsd2tPWS1qZUFFY1VhTGg3d1hGOGJfS0dVTDk1R1JkUlV3dk9QaTRmTkNDMmVpZXNhSnpSX1Q0TTNLYVgyNXd6T09kb3dfbnh2dnpORkVIdnhMNWx6NElvTTJXNFk4eFRNWGhiYlE5aXY5VzlhZU9yV3UxWFkxSzdSbmplVTRZWlJseU9jWU9uRDJva28tdzhZUzN5RDFtdG5qM2xyMXZjbmFsYXZtbW9OTUhKNkh4Z19ISFR1cXNmTFV2S0hGZHpIcmVmRUZROTNYWl9sYWxPX0J1Z0o2YWY2V0xCU2hYbFE?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:22:33+00:00", "published_display": "13 Jul 2026 09:22", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week \u2013 Which One Has More Upside?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxOM1R3OUJycTdidVpWMWpkWXBpTHlMYkx0MHBiSzNZd19INm9TR0Jwdks5WFFZdUc0a1JzUjhiUVFmdWYySERLSDJKUFR4T0FqdW5sdTluX3VMaDBjM01VaW13MG8yUHdBeUtsVnNKZTBJblpkS3hrVHdVc2pYN21WYUd1WXdnNmJjRS1DZ2EtVEFaX0UtRFJEMEdmVDJPMk9Wekg5bnZXQ2ZEY1NYcjZJdmhyaTZjbFVWQ3kzZXZnWWNfd2I5S3Boc2RtUlpWZ3JnWmtoQWgtTnZlc2M?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-13T04:42:21+00:00", "published_display": "13 Jul 2026 04:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout", "summary": "", "url": "https://finance.yahoo.com/m/4a69b719-3b8d-34e5-bd28-3ea282cb0be8/moderna-drops-11%25%2C.html", "source_name": "24/7 Wall St.", "published_at": "2026-07-10T16:04:38+00:00", "published_display": "10 Jul 2026 16:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics (SRPT) Proxy filing Summary", "summary": "Sarepta Therapeutics (SRPT) has released a summary of its proxy filing for the upcoming Annual Meeting scheduled for June 4, 2026. The filing outlines key proposals including the election of five Class I directors, executive compensation, equity and stock purchase plans, and audi", "url": "https://quartr.com/events/sarepta-therapeutics-srpt-proxy-filing_ontTKMf9", "source_name": "Quartr", "published_at": "2026-07-09T23:40:01", "published_display": "09 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Analyst Sees 34% Upside For SRPT Stock \u2014 Here's Why They Expect A Sustained Rally Next", "summary": "Wolfe Research upgraded Sarepta Therapeutics (SRPT) to 'Outperform' with a $27 price target, citing potential catalysts like new data in H2 2026 and readthrough from Novartis's neuromuscular disease programs. The firm believes SRPT, despite recent transient gains, is poised for a", "url": "https://stocktwits.com/news-articles/markets/equity/srpt-stock-bullish-upgrade-novartis-readthrough-other-catalysts/cZmovIpR7nb", "source_name": "Stocktwits", "published_at": "2026-07-09T10:47:06", "published_display": "09 Jul 2026 10:47", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research upgrades Sarepta Therapeutics stock rating on pipeline outlook", "summary": "Wolfe Research upgraded Sarepta Therapeutics (NASDAQ:SRPT) to Outperform from Peerperform, setting a price target of $27.00, implying a 33% upside. The upgrade is attributed to anticipated data releases, increased investor focus on the company", "url": "https://www.investing.com/news/analyst-ratings/wolfe-research-upgrades-sarepta-therapeutics-stock-rating-on-pipeline-outlook-93CH-4782724", "source_name": "Investing.com", "published_at": "2026-07-08T21:41:37", "published_display": "08 Jul 2026 21:41", "sentiment": "positive", "sentiment_pct": 91, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics (SRPT) Q4 2025 earnings summary", "summary": "Sarepta Therapeutics reported strong financial results for Q4 and full-year 2025, with $2.2 billion in total revenues and a positive operating cash flow. The company launched ELEVIDYS in Japan, which triggered a $40 million milestone, and saw durable benefits from its three-year ", "url": "https://quartr.com/events/sarepta-therapeutics-inc-srpt-q4-2025_ontTyR2M", "source_name": "Quartr", "published_at": "2026-07-08T10:09:24", "published_display": "08 Jul 2026 10:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Sarepta Therapeutics, Inc. \u2013 NASDAQ:SRPT", "summary": "This article provides financial data for Sarepta Therapeutics, Inc. (NASDAQ: SRPT), specifically focusing on its \"Price to book forward\" metric. It appears to be a stub or a data point from a larger financial platform like TradingView, indicating the value and change of this fina", "url": "https://www.tradingview.com/symbols/NASDAQ-SRPT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T01:40:16", "published_display": "08 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Sarepta Therapeutics, Inc. \u2013 LSE:0L35", "summary": "This article displays financial information for Sarepta Therapeutics, Inc., specifically its \"Price to book forward.\" It shows the company's ticker symbol (0L35) on the London Stock Exchange and outlines the various sections available on the TradingView platform for this security", "url": "https://www.tradingview.com/symbols/LSE-0L35/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T23:11:19", "published_display": "07 Jul 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Sarepta Therapeutics (SRPT) Is Up 12.7% After FDA Accepts sNDAs Backed By ESSENCE Data", "summary": "Sarepta Therapeutics' stock rose 12.7% after the FDA accepted supplemental New Drug Applications (sNDAs) for its Duchenne muscular dystrophy (DMD) therapies, AMONDYS 45 and VYONDYS 53, for conversion to traditional approvals. These applications are backed by Phase 3 ESSENCE data ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/why-sarepta-therapeutics-srpt-is-up-127-after-fda-accepts-sn", "source_name": "Simply Wall Street", "published_at": "2026-07-07T16:11:33", "published_display": "07 Jul 2026 16:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Sarepta Therapeutics, Inc. \u2013 LSE:0L35", "summary": "This article provides financial data for Sarepta Therapeutics, Inc. (LSE:0L35), specifically focusing on its enterprise value to EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) forward metric. It appears to be a stub or data-point article from TradingView", "url": "https://www.tradingview.com/symbols/LSE-0L35/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T02:09:44", "published_display": "07 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Sarepta Therapeutics, Inc. \u2013 LSE:0L35", "summary": "This article provides financial information for Sarepta Therapeutics, Inc. (LSE:0L35), specifically focusing on its forward price-to-earnings ratio. The content primarily lists market data sources and disclaimers from TradingView and its partners. It does not provide specific val", "url": "https://www.tradingview.com/symbols/LSE-0L35/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T11:42:19", "published_display": "06 Jul 2026 11:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Sarepta Therapeutics, Inc. \u2013 LSE:0L35", "summary": "This article provides financial data for Sarepta Therapeutics, Inc. (LSE:0L35) with a specific focus on its enterprise value to EBIT forward. It is presented in a data-centric format common on financial platforms like TradingView, indicating the period, value, and change metrics ", "url": "https://www.tradingview.com/symbols/LSE-0L35/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T22:40:10", "published_display": "05 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SRPT - Sarepta Therapeutics Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Sarepta Therapeutics Inc (SRPT), including its stock performance, key financial metrics, and market volatility data. It lists various ratios, growth rates, insider and institutional ownership, and analyst recommendations. The", "url": "https://finviz.com/stock?t=SRPT&ta=1&p=m&ty=ocv&b=2&r=y5&ov=list_strike&s=21", "source_name": "Finviz", "published_at": "2026-07-04T11:09:57", "published_display": "04 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Sarepta Therapeutics, Inc. Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold stocks of Sarepta Therapeutics, Inc. It provides detailed information for each ETF, including market value, weight of Sarepta Therapeutics stock, issuer, management style, focus, expense ratio, assets under managem", "url": "https://www.tradingview.com/symbols/BX-AB3A/etfs/", "source_name": "TradingView", "published_at": "2026-07-04T09:41:11", "published_display": "04 Jul 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Sarepta Therapeutics Inc (SRPT)", "summary": "This article analyzes the historical performance of an investment in Sarepta Therapeutics Inc (SRPT), detailing returns over 1, 5, and 10 years, and comparing them to the S&P 500. It also provides an in-depth company profile, outlining Sarepta's focus on genetic medicines for rar", "url": "https://www.stocktitan.net/tools/stock-return-calculator/SRPT", "source_name": "Stock Titan", "published_at": "2026-07-04T08:41:11", "published_display": "04 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps \u2014 CEO Still Sees Return To Growth", "summary": "Sarepta Therapeutics (SRPT) stock fell 7% after-hours despite beating Q1 2026 revenue and earnings expectations, primarily due to lower sales of its gene therapy Elevidys. The therapy's sales were impacted by safety concerns and a narrowed addressable patient population. CEO Doug", "url": "https://stocktwits.com/news-articles/markets/equity/srpt-stock-plunges-after-hours-as-elevidys-demand-slumps-ceo-still-sees-return-to-growth/cZQzkcWReOx", "source_name": "Stocktwits", "published_at": "2026-07-04T08:40:10", "published_display": "04 Jul 2026 08:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics, Inc. Stock 12\u2011Month Price Target Cut to $22, Implies 14% Upside", "summary": "Sarepta Therapeutics, Inc. (SRPT) has seen its average 12-month price target reduced from $22.67 to $22 by 23 analysts, despite forecasts ranging from $5 to $38 per share. This new target implies a 14% potential upside based on the July 2 closing price. The consensus rating for S", "url": "https://www.tradingview.com/news/tradingview:f7ec662db2298:0-sarepta-therapeutics-inc-stock-12-month-price-target-cut-to-22-implies-14-upside/", "source_name": "TradingView", "published_at": "2026-07-03T03:11:42", "published_display": "03 Jul 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics Jumps 6.5% Amid Sector-Wide Rally", "summary": "Sarepta Therapeutics saw its stock surge by 6.5% on Thursday, closing at $19.38 per share amidst a broad sector-wide rally in biotechnology stocks. The gene therapy developer's gain outpaced several peers, fueled by investor rotation into the sector rather than company-specific n", "url": "https://news.alphastreet.com/sarepta-therapeutics-jumps-6-5-amid-sector-wide-rally/", "source_name": "AlphaStreet", "published_at": "2026-07-02T16:10:07", "published_display": "02 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $5", "summary": "H.C. Wainwright has reaffirmed its Sell rating for Sarepta Therapeutics (SRPT.US) and maintained a target price of $5. This indicates a continued bearish outlook on the company's stock by the analytical firm.", "url": "https://www.moomoo.com/news/post/72327261/hc-wainwright-maintains-sarepta-therapeutics-srptus-with-sell-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-02T07:40:31", "published_display": "02 Jul 2026 07:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail", "summary": "Sarepta Therapeutics has secured an early 2027 FDA decision for full approval of its Duchenne muscular dystrophy exon-skipping therapies, Amondys 45 and Vyondys 53, despite their failure to improve motor function in a confirmatory Phase 3 trial. The FDA's acceptance of the applic", "url": "https://www.biospace.com/fda/sarepta-secures-early-2027-fda-decision-for-duchenne-drugs-pushing-past-confirmatory-fail", "source_name": "BioSpace", "published_at": "2026-07-01T11:39:51", "published_display": "01 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Accepts sNDAs for Sarepta's AMONDYS 45 and VYONDYS 53, Targeting Traditional Approval in Duchenne", "summary": "The FDA has accepted Sarepta's supplemental New Drug Applications (sNDAs) for Amondys 45 and Vyondys 53, aiming to convert their accelerated approvals to traditional approvals for Duchenne muscular dystrophy. The decision is based on data from the Phase 3 ESSENCE confirmatory tri", "url": "https://www.biopharminternational.com/view/fda-accepts-sndas-for-sarepta-s-amondys-45-and-vyondys-53-targeting-traditional-approval-in-duchenne", "source_name": "BioPharm International", "published_at": "2026-07-01T06:39:04", "published_display": "01 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics (SRPT) Following FDA Filings And The Case For A Reset Valuation", "summary": "Sarepta Therapeutics (SRPT) is under renewed scrutiny after the FDA accepted supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53. Despite this regulatory progress, the stock has experienced significant declines over the past 90 days and three years, making investors ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/sarepta-therapeutics-srpt-following-fda-filings-and-the-case", "source_name": "Simply Wall Street", "published_at": "2026-07-01T06:39:04", "published_display": "01 Jul 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Sarepta Therapeutics, Inc. granted equity awards to 30 new employees in the second quarter of 2026 as a material inducement for their employment. These awards, totaling 151,305 restricted stock units (RSUs), were approved by the Compensation Committee and are in accordance with N", "url": "https://www.businesswire.com/news/home/20260630221318/en/Sarepta-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4", "source_name": "Business Wire", "published_at": "2026-07-01T06:39:04", "published_display": "01 Jul 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Accepts Sarepta's sNDAs for Casimersen and Golodirsen for Duchenne Muscular Dystrophy", "summary": "The FDA has accepted Sarepta Therapeutics' supplemental new drug applications (sNDAs) for casimersen (Amondys 45) and golodirsen (Vyondys 53) for Duchenne muscular dystrophy (DMD), setting a PDUFA target action date of February 28, 2027. These submissions aim to convert the exist", "url": "https://www.neurologylive.com/view/fda-accepts-sarepta-sndas-casimersen-golodirsen-dmd", "source_name": "NeurologyLive", "published_at": "2026-07-01T03:39:04", "published_display": "01 Jul 2026 03:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45\u00ae and VYONDYS 53\u00ae", "summary": "Sarepta Therapeutics announced that the FDA has accepted supplemental New Drug Applications (sNDAs) for AMONDYS 45\u00ae and VYONDYS 53\u00ae for Duchenne muscular dystrophy (DMD), with a PDUFA target action date of February 28, 2027. These sNDAs aim to convert the accelerated approvals of", "url": "https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-fda-acceptance-sndas-amondys-45r-and-vyondys", "source_name": "Sarepta Therapeutics", "published_at": "2026-06-30T18:39:51", "published_display": "30 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Accepts Sarepta's Applications for Full Approval of Two DMD Treatments", "summary": "The FDA has accepted Sarepta's applications for Amondys 45 and Vyondys 53, setting a target decision date of February 28, 2027, for full approval of these Duchenne muscular dystrophy (DMD) treatments. The applications are supported by clinical and real-world data showing positive", "url": "https://intellectia.ai/news/stock/fda-accepts-sareptas-applications-for-full-approval-of-two-dmd-treatments", "source_name": "Intellectia AI", "published_at": "2026-06-30T17:11:20", "published_display": "30 Jun 2026 17:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA to review Sarepta\u2019s Duchenne drugs, with decision due Feb. 28, 2027", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQZDVjR000em1YQjlrQnhfSWl6VXNpbWYzMkEyeVdOUXlVZkpLVklMOGtpOVgtc0dvTTB5b2hEY1A5UGEzTndJckM2NlJBeXBzTkludUVlSmR5R3dwQWtxMUxtWHNuTmFBZXE1em5ZTUFVUzlQT0ZzcG1hUGZadmxoYU5LNzhfa1FJNm1qRWRCSHk4aVZ3bGlVbVBvUUd5NXlaTVhEeGN5cGxiUV80ZldLci1PWm9oZEZs?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SRPT Stock Climbs After Sarepta Seeks Permanent FDA Nod For Two Duchenne Therapies", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOR3hMNjFwMmxxQ0lwNzdZY19OS1pSUmtpV2tOOE9TX0xOLTJRbTJiZDkwQ3JFUHFNX0JMaU8yOFRPOUNvdHF5NUhxTWRxRHEwZVRLWk5MY0d0alllbGdKNG55dW1xSUxUb2pSdWwycWhlSGNZSWdobmQybDNOdDNvS1d6X0JnUDRWaG5XVkVsMXlxV0hZZl84?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring a Potential 43.7% Upside in the Biotech Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxPeGtMV3dsYmlHdnZYTnBPcUdBb0l0Q3hnZy1nNEl1UklOX3ZiMzcxd3NGOElOcF9ybEttYldnOHpCOW5qMExmc25XYkdhTU9UNlBNTExiMm5YdWJpS2o2cXpMSTNGcndtT1B3ekVwOVg4TmNtU0ViVFJHRXN1OWhVbENNZ0ZTcHJrTnFNOUdNTjlselA3Zld4TUhjQWIyUU1tYno4cFJOMFhhWWhBRS1MeGw3UDFHYV9Ea1JZZDZDcU1SYVctYlp1a3RZRVRJVVgzVWlISzNkT2hjU1duMERhU2xUREFCZw?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQWTEzWXI2NXhNMFlmREM0Yzl0elQ0WWtuTG1uV0ZWUnlaMG9Feno0OVg3cGV2WXZqZ0U1NVpFWTZobGdZU01GUF8tU01fZWVLUDFRSXlxV0oxamdIbEFIbTM1cDVxNjFKQkM1RmZjMWVlVW9ITFBVYmIyOENmMG5Xd0ZnYm1DZkMxcHN0c21BaDNLTUF2b0VDenEtU05oOHk4MmVQMTRn?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring a 23% Potential Upside in the Biotech Arena", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxQRmZDQzFrS0t1SGk1OGx0SF8xZVhzSEIyVEtyRklrYjdrWHpXbGYzalV4UFZZbzNnWmkyaEppWl9uRDJIcUFWLWRJWkJqQ2RkeUp3cWZUYkxoU2Y2MWVqVnplakpNdXhUNXhMQmgxeTV3bjY1N3d0cUhFbGVOcEl5RVZZMV96Q3B4VVVQUVFVbzEycWNFTUEzUHhORHlZM2NIZ2pfMU5weTdsRkZJMmFlTUVwb1pSUnEycnYxWlpjMF9Pb0VndDNQMGMtemEtUjdxNzIxa1lvdi04MUVNOTlhaWdR?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "In Solid Cash Position, Sarepta Therapeutics Inc (SRPT) Outlines 2026 Priorities", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQdTh2S3pWR3ZmN3YyN0twbGhqb2tROXV6REtUN21xODh4MWhNR0pEb3VKb1N6VE9UUkprN3lQb052OGl2ZE5FdUdsMEtlWkIyRE1wTm1OR1RabkZYQm10TExvTFcxMk5iaUU2WlhkaFIyekdna2pRRGpGejBHZjA2MkV3Zkc3bXpFbHR4MFpSem5tZ0dvc0liSVZ6Y2xxMU9HREtwU2Y3N0pwSTQyWFE?oc=5", "source_name": "Market source", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQZVBVbDFVMnJpUlo4NVN3SDVmQ01pMEE2NktHbVdhS0dUenotaUptTnJnOWF2dXhuUm5hdHozbHFCM1AwWG84LVA3OElZLW1SVC1JWWpMT2I3WGtESmN2WlZncUY4TlhPR1U2eDNFa1dURlVVWlBRUHVWNHl0ZzJHdDNmY2VFTU9OX2s2aFFEa1NIZDg1TFVDQ1pRQjFESWlXVnJWbGJsUjRLckRiV1Zr?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Elevidys Matters For Sarepta Therapeutics Inc (SRPT) Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOR3hMTUpuOVg4X3dmZ056QmVEdko1SkUxbGJIcE00ZHBBNUpjN2JYSGxIOV9HT3lfLWotckZLRTVYUEdaT29fMFRZU3BtbjF3ZFY3bWY0emJYSkJHLUh6STZzV0VXSXBfMTJoSDJuVTIyMlJDdEZpQmZmdGdfUXlqM1NyWlhuMFY5Xzk5YUR6eXFzRF9KU0ZoeWNMMjRQZmR5NFhpZTNtMTVma21WbWpF?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Solid Earnings, But It Is Not All Good News", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Sarepta Therapeutics (SRPT) A Potential Opportunity After Sharp Multi\u2011Year Share Price Declines?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPVlY0ZUozMVB5WWlYaXllUjEyX1J5eGsxVnFXNUxaZG0xNGUycy1OeE12UjJhdVQzREc5RFdoVnRvd3VCUzNrUkxFUHJ3ZC03MGJHSExMSF9HSDJTaXRaMWhROXhXTzlCdlFBYm8xZXRxekdoWDhWYTNLa1dNVjNhWi1xY1NfNnp1NFlhVmx2dFpHMWkwWXZvMGdrQ01uejFpaGEwWk9Fdnk2SVNEcGN4VkpONWtDTl9ybm5vbzJRajQtNm5pOTczZDB4a2o?oc=5", "source_name": "Sarepta Therapeutics", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[10-Q] Sarepta Therapeutics, Inc. Quarterly Earnings Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOQkR4Nlp0a2xyR0ZkQXRtNl9wUWpieEd3dHFPR3l2cV9ldmphaTd1eUhvMnZEYS1WcWxGRlRkTWRKVTJJbWJSS0dTaHMxYVlDbkQwVWhkdVVGVVRFMGgzYnl2RDZUTFZvWXNRNUp3Y2FsbGJMc0x0RUxCN29rNno3b0V4QU9yYk04NWpwaE95cUMyTmVQVkpJMjREcDNNRktzbHZFVk9BSUI3LTFkeGFsNTNhYjR1Z1Bx?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNaS1Rb0lPUi1jNlpkSGpWd1g1V3FYN05mclpZamY3RDFNTGxKZG5wTVdQdl9TaGI0aXBQVVEzY05MLVRYSmk0ZDAwaGx5YmpaMmNPY0xQNHBoSTNzdjJwTXRxeXZEMkp6MHhvLTFyS3pvWDdFRHIzWmRnME9UX3hGLXBSUC1QaEpvUFRmNXhxY01IeEE3Wm1GZ1NKekw2STVQ?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQdFhHNUg2SkVFMGhReXZRZ0gtemdWTGVpTWJ0aEdrRFdJbGFHSnRlZFJ5T1J6V25ZWDdFSV9uMFZMQjFfRXBfN0dscWtQZHA3NDF4b0xFeGJMVTNnTy1KNFZqckMzTUlKc0VXeFVhQllaeWduS25GWDNiNGV6dW81Y1JmQkp2U0FRMnRLVlp6NHd4My1TNno5bkdpdm00VlA5Z3VSMmxqaS00TGdVOEZYVDFXQ3M1UmlpVmlPdDR3Q1dWMnltaXhwRFBBN2xfVUJt?oc=5", "source_name": "Sarepta Therapeutics", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics (SRPT) Q4 Loss Deepens And Tests Bullish Profitability Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOaTdSV3g3Mk5TU1g5SzNKUk1kTnRLRHJmRlVRVS0ycWJuZktLRkZCbU4xa1dnTUlqZHV4ekZISHFxU0dJdFlkUUhJMlZ6LVJqdlJCbFltT0tXMk1VVHBmNVgzZDRNTC1WZVBRSWJGQzRmN0RtU0sxUC0wdzhNZTFCdHdUOVRwSXZ5UmtvOS1xb0xVM1pqblJCRTdjSWZxdlZtSkhqUjBwOXpxWGhkMm1HTk1iTzljdUs3bmxnTzI4bTZoWGtRTFBhSWM0SUtFT1Q2dDNB?oc=5", "source_name": "Sarepta Therapeutics", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues Despite A 35% Share Price Rise", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-04T08:00:00+00:00", "published_display": "04 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta stock ticks up as FDA finalises tighter Elevidys label", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBGcDhsMmJBRVZVbW4xZlhiejBxcTBEUVZlRWJVTGNUQ1Y3WjRHaWxxRFdYeVdHWExJWnAtWGk2UHc1NjRxUmtPX1FUTVVhci1rZldz?oc=5", "source_name": "FirstWord PHARMA", "published_at": "2025-11-14T08:00:00+00:00", "published_display": "14 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "SRPT Stock Clocks Highest Daily Gain In Nearly 8 Years After Rare Muscle Disorders Study Data But Wall Street's Not Wholly Convinced", "summary": "Sarepta Therapeutics (SRPT) shares jumped 35% after releasing early clinical data for its rare muscle disorder programs, DM1 and FSHD1. While some analysts found the data promising, others expressed caution due to limitations in the data and safety concerns. The company's investi", "url": "https://stocktwits.com/news-articles/markets/equity/srpt-stock-clocks-highest-daily-gain-in-nearly-8-years-after-rare-muscle-disorders-study-data/cZ3pTn6RIjd", "source_name": "Stocktwits", "published_at": "2026-07-16T12:10:30", "published_display": "16 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trading Systems Reacting to (SRPT) Volatility", "summary": "This article from Stock Traders Daily discusses the volatility of Sarepta Therapeutics Inc. (NASDAQ: SRPT), highlighting conflicting sentiment across different time horizons. It provides AI-generated trading strategies including position trading, momentum breakout, and risk hedgi", "url": "https://news.stocktradersdaily.com/news_release/17/Trading_Systems_Reacting_to_SRPT_Volatility_071626014001_1784180401.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-16T01:40:32", "published_display": "16 Jul 2026 01:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Sarepta Therapeutics (SRPT) Undervalued Following FDA Progress On AMONDYS 45 And VYONDYS 53?", "summary": "Sarepta Therapeutics (SRPT) is being re-evaluated after the FDA accepted supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53, Duchenne muscular dystrophy therapies. While the stock has seen a recent 30-day rebound, its long-term shareholder returns remain negative. T", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/is-sarepta-therapeutics-srpt-undervalued-following-fda-progr", "source_name": "Simply Wall Street", "published_at": "2026-07-15T12:10:30", "published_display": "15 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Sarepta Therapeutics, Inc. (SRPT)", "summary": "Johnson Fistel, PLLP is investigating potential claims on behalf of long-term shareholders of Sarepta Therapeutics, Inc. (SRPT) who held shares continuously since before June 22, 2023. The investigation concerns alleged breaches of fiduciary duty by Sarepta's officers and directo", "url": "https://supplychaindigital.com/globenewswire/3326258", "source_name": "Supply Chain Digital", "published_at": "2026-07-14T08:11:46", "published_display": "14 Jul 2026 08:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Following FDA sNDA Acceptance Is Sarepta Therapeutics (SRPT) Still Undervalued?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPZldZR01LaFJWSjhqaEFTdi1tRzZISGpmajgyZlk4aEhfTmFQc0tpM2VlNnlYNVFDRl9xUW9CN1JmVG8zbEthbmR2NXZDM3R3dGJnWU0zZXQ2NTBMS1dOZHZmZkQ3WERIcGdEdC1oYUFOaTFPWHk1N1gtNV9FeWFvVW1IdmtjNEZiZ1o1dkFUazQ3eEc4R2M0UDRxcU5wQUU?oc=5", "source_name": "Market source", "published_at": "2026-07-14T01:10:00+00:00", "published_display": "14 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For Sarepta Therapeutics (SRPT) Could Change Following FDA sNDA Acceptance On DMD Therapies", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxObk51bU1mR3FzU2NEWnN0YnJqQkloRVVSMDR5aHZoNlJ2UHVqNGlZdWdIQ2MxNUh0bGM5LVp5dTA3ajEzQ2ZpczFoWkE4YjM4dDhsTWVtUzk0a2xGYnZMSWh1STVDLTljQWg0Sm1mSDJoUkhvR1RCVzcxUUJKOWkwZHhfd3hVZHdhNWVMMGU5THE1TlRNeXZwVjhtRWg?oc=5", "source_name": "Market source", "published_at": "2026-07-14T00:22:00+00:00", "published_display": "14 Jul 2026 00:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics (SRPT) Stock Analysis: Evaluating a 16.53% Potential Upside Amidst a Volatile Biotech Landscape", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxOUG1ibFpjUk42WE1FblNsd2tPWS1qZUFFY1VhTGg3d1hGOGJfS0dVTDk1R1JkUlV3dk9QaTRmTkNDMmVpZXNhSnpSX1Q0TTNLYVgyNXd6T09kb3dfbnh2dnpORkVIdnhMNWx6NElvTTJXNFk4eFRNWGhiYlE5aXY5VzlhZU9yV3UxWFkxSzdSbmplVTRZWlJseU9jWU9uRDJva28tdzhZUzN5RDFtdG5qM2xyMXZjbmFsYXZtbW9OTUhKNkh4Z19ISFR1cXNmTFV2S0hGZHpIcmVmRUZROTNYWl9sYWxPX0J1Z0o2YWY2V0xCU2hYbFE?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:22:33+00:00", "published_display": "13 Jul 2026 09:22", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week \u2013 Which One Has More Upside?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxOM1R3OUJycTdidVpWMWpkWXBpTHlMYkx0MHBiSzNZd19INm9TR0Jwdks5WFFZdUc0a1JzUjhiUVFmdWYySERLSDJKUFR4T0FqdW5sdTluX3VMaDBjM01VaW13MG8yUHdBeUtsVnNKZTBJblpkS3hrVHdVc2pYN21WYUd1WXdnNmJjRS1DZ2EtVEFaX0UtRFJEMEdmVDJPMk9Wekg5bnZXQ2ZEY1NYcjZJdmhyaTZjbFVWQ3kzZXZnWWNfd2I5S3Boc2RtUlpWZ3JnWmtoQWgtTnZlc2M?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-13T04:42:21+00:00", "published_display": "13 Jul 2026 04:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout", "summary": "", "url": "https://finance.yahoo.com/m/4a69b719-3b8d-34e5-bd28-3ea282cb0be8/moderna-drops-11%25%2C.html", "source_name": "24/7 Wall St.", "published_at": "2026-07-10T16:04:38+00:00", "published_display": "10 Jul 2026 16:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics (SRPT) Proxy filing Summary", "summary": "Sarepta Therapeutics (SRPT) has released a summary of its proxy filing for the upcoming Annual Meeting scheduled for June 4, 2026. The filing outlines key proposals including the election of five Class I directors, executive compensation, equity and stock purchase plans, and audi", "url": "https://quartr.com/events/sarepta-therapeutics-srpt-proxy-filing_ontTKMf9", "source_name": "Quartr", "published_at": "2026-07-09T23:40:01", "published_display": "09 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Analyst Sees 34% Upside For SRPT Stock \u2014 Here's Why They Expect A Sustained Rally Next", "summary": "Wolfe Research upgraded Sarepta Therapeutics (SRPT) to 'Outperform' with a $27 price target, citing potential catalysts like new data in H2 2026 and readthrough from Novartis's neuromuscular disease programs. The firm believes SRPT, despite recent transient gains, is poised for a", "url": "https://stocktwits.com/news-articles/markets/equity/srpt-stock-bullish-upgrade-novartis-readthrough-other-catalysts/cZmovIpR7nb", "source_name": "Stocktwits", "published_at": "2026-07-09T10:47:06", "published_display": "09 Jul 2026 10:47", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research upgrades Sarepta Therapeutics stock rating on pipeline outlook", "summary": "Wolfe Research upgraded Sarepta Therapeutics (NASDAQ:SRPT) to Outperform from Peerperform, setting a price target of $27.00, implying a 33% upside. The upgrade is attributed to anticipated data releases, increased investor focus on the company", "url": "https://www.investing.com/news/analyst-ratings/wolfe-research-upgrades-sarepta-therapeutics-stock-rating-on-pipeline-outlook-93CH-4782724", "source_name": "Investing.com", "published_at": "2026-07-08T21:41:37", "published_display": "08 Jul 2026 21:41", "sentiment": "positive", "sentiment_pct": 91, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics (SRPT) Q4 2025 earnings summary", "summary": "Sarepta Therapeutics reported strong financial results for Q4 and full-year 2025, with $2.2 billion in total revenues and a positive operating cash flow. The company launched ELEVIDYS in Japan, which triggered a $40 million milestone, and saw durable benefits from its three-year ", "url": "https://quartr.com/events/sarepta-therapeutics-inc-srpt-q4-2025_ontTyR2M", "source_name": "Quartr", "published_at": "2026-07-08T10:09:24", "published_display": "08 Jul 2026 10:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Sarepta Therapeutics, Inc. \u2013 NASDAQ:SRPT", "summary": "This article provides financial data for Sarepta Therapeutics, Inc. (NASDAQ: SRPT), specifically focusing on its \"Price to book forward\" metric. It appears to be a stub or a data point from a larger financial platform like TradingView, indicating the value and change of this fina", "url": "https://www.tradingview.com/symbols/NASDAQ-SRPT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T01:40:16", "published_display": "08 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Sarepta Therapeutics, Inc. \u2013 LSE:0L35", "summary": "This article displays financial information for Sarepta Therapeutics, Inc., specifically its \"Price to book forward.\" It shows the company's ticker symbol (0L35) on the London Stock Exchange and outlines the various sections available on the TradingView platform for this security", "url": "https://www.tradingview.com/symbols/LSE-0L35/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T23:11:19", "published_display": "07 Jul 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Sarepta Therapeutics (SRPT) Is Up 12.7% After FDA Accepts sNDAs Backed By ESSENCE Data", "summary": "Sarepta Therapeutics' stock rose 12.7% after the FDA accepted supplemental New Drug Applications (sNDAs) for its Duchenne muscular dystrophy (DMD) therapies, AMONDYS 45 and VYONDYS 53, for conversion to traditional approvals. These applications are backed by Phase 3 ESSENCE data ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/why-sarepta-therapeutics-srpt-is-up-127-after-fda-accepts-sn", "source_name": "Simply Wall Street", "published_at": "2026-07-07T16:11:33", "published_display": "07 Jul 2026 16:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Sarepta Therapeutics, Inc. \u2013 LSE:0L35", "summary": "This article provides financial data for Sarepta Therapeutics, Inc. (LSE:0L35), specifically focusing on its enterprise value to EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) forward metric. It appears to be a stub or data-point article from TradingView", "url": "https://www.tradingview.com/symbols/LSE-0L35/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T02:09:44", "published_display": "07 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Sarepta Therapeutics, Inc. \u2013 LSE:0L35", "summary": "This article provides financial information for Sarepta Therapeutics, Inc. (LSE:0L35), specifically focusing on its forward price-to-earnings ratio. The content primarily lists market data sources and disclaimers from TradingView and its partners. It does not provide specific val", "url": "https://www.tradingview.com/symbols/LSE-0L35/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T11:42:19", "published_display": "06 Jul 2026 11:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Sarepta Therapeutics, Inc. \u2013 LSE:0L35", "summary": "This article provides financial data for Sarepta Therapeutics, Inc. (LSE:0L35) with a specific focus on its enterprise value to EBIT forward. It is presented in a data-centric format common on financial platforms like TradingView, indicating the period, value, and change metrics ", "url": "https://www.tradingview.com/symbols/LSE-0L35/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T22:40:10", "published_display": "05 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SRPT - Sarepta Therapeutics Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Sarepta Therapeutics Inc (SRPT), including its stock performance, key financial metrics, and market volatility data. It lists various ratios, growth rates, insider and institutional ownership, and analyst recommendations. The", "url": "https://finviz.com/stock?t=SRPT&ta=1&p=m&ty=ocv&b=2&r=y5&ov=list_strike&s=21", "source_name": "Finviz", "published_at": "2026-07-04T11:09:57", "published_display": "04 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Sarepta Therapeutics, Inc. Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold stocks of Sarepta Therapeutics, Inc. It provides detailed information for each ETF, including market value, weight of Sarepta Therapeutics stock, issuer, management style, focus, expense ratio, assets under managem", "url": "https://www.tradingview.com/symbols/BX-AB3A/etfs/", "source_name": "TradingView", "published_at": "2026-07-04T09:41:11", "published_display": "04 Jul 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Sarepta Therapeutics Inc (SRPT)", "summary": "This article analyzes the historical performance of an investment in Sarepta Therapeutics Inc (SRPT), detailing returns over 1, 5, and 10 years, and comparing them to the S&P 500. It also provides an in-depth company profile, outlining Sarepta's focus on genetic medicines for rar", "url": "https://www.stocktitan.net/tools/stock-return-calculator/SRPT", "source_name": "Stock Titan", "published_at": "2026-07-04T08:41:11", "published_display": "04 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps \u2014 CEO Still Sees Return To Growth", "summary": "Sarepta Therapeutics (SRPT) stock fell 7% after-hours despite beating Q1 2026 revenue and earnings expectations, primarily due to lower sales of its gene therapy Elevidys. The therapy's sales were impacted by safety concerns and a narrowed addressable patient population. CEO Doug", "url": "https://stocktwits.com/news-articles/markets/equity/srpt-stock-plunges-after-hours-as-elevidys-demand-slumps-ceo-still-sees-return-to-growth/cZQzkcWReOx", "source_name": "Stocktwits", "published_at": "2026-07-04T08:40:10", "published_display": "04 Jul 2026 08:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics, Inc. Stock 12\u2011Month Price Target Cut to $22, Implies 14% Upside", "summary": "Sarepta Therapeutics, Inc. (SRPT) has seen its average 12-month price target reduced from $22.67 to $22 by 23 analysts, despite forecasts ranging from $5 to $38 per share. This new target implies a 14% potential upside based on the July 2 closing price. The consensus rating for S", "url": "https://www.tradingview.com/news/tradingview:f7ec662db2298:0-sarepta-therapeutics-inc-stock-12-month-price-target-cut-to-22-implies-14-upside/", "source_name": "TradingView", "published_at": "2026-07-03T03:11:42", "published_display": "03 Jul 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics Jumps 6.5% Amid Sector-Wide Rally", "summary": "Sarepta Therapeutics saw its stock surge by 6.5% on Thursday, closing at $19.38 per share amidst a broad sector-wide rally in biotechnology stocks. The gene therapy developer's gain outpaced several peers, fueled by investor rotation into the sector rather than company-specific n", "url": "https://news.alphastreet.com/sarepta-therapeutics-jumps-6-5-amid-sector-wide-rally/", "source_name": "AlphaStreet", "published_at": "2026-07-02T16:10:07", "published_display": "02 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $5", "summary": "H.C. Wainwright has reaffirmed its Sell rating for Sarepta Therapeutics (SRPT.US) and maintained a target price of $5. This indicates a continued bearish outlook on the company's stock by the analytical firm.", "url": "https://www.moomoo.com/news/post/72327261/hc-wainwright-maintains-sarepta-therapeutics-srptus-with-sell-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-02T07:40:31", "published_display": "02 Jul 2026 07:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail", "summary": "Sarepta Therapeutics has secured an early 2027 FDA decision for full approval of its Duchenne muscular dystrophy exon-skipping therapies, Amondys 45 and Vyondys 53, despite their failure to improve motor function in a confirmatory Phase 3 trial. The FDA's acceptance of the applic", "url": "https://www.biospace.com/fda/sarepta-secures-early-2027-fda-decision-for-duchenne-drugs-pushing-past-confirmatory-fail", "source_name": "BioSpace", "published_at": "2026-07-01T11:39:51", "published_display": "01 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Accepts sNDAs for Sarepta's AMONDYS 45 and VYONDYS 53, Targeting Traditional Approval in Duchenne", "summary": "The FDA has accepted Sarepta's supplemental New Drug Applications (sNDAs) for Amondys 45 and Vyondys 53, aiming to convert their accelerated approvals to traditional approvals for Duchenne muscular dystrophy. The decision is based on data from the Phase 3 ESSENCE confirmatory tri", "url": "https://www.biopharminternational.com/view/fda-accepts-sndas-for-sarepta-s-amondys-45-and-vyondys-53-targeting-traditional-approval-in-duchenne", "source_name": "BioPharm International", "published_at": "2026-07-01T06:39:04", "published_display": "01 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics (SRPT) Following FDA Filings And The Case For A Reset Valuation", "summary": "Sarepta Therapeutics (SRPT) is under renewed scrutiny after the FDA accepted supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53. Despite this regulatory progress, the stock has experienced significant declines over the past 90 days and three years, making investors ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/sarepta-therapeutics-srpt-following-fda-filings-and-the-case", "source_name": "Simply Wall Street", "published_at": "2026-07-01T06:39:04", "published_display": "01 Jul 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Sarepta Therapeutics, Inc. granted equity awards to 30 new employees in the second quarter of 2026 as a material inducement for their employment. These awards, totaling 151,305 restricted stock units (RSUs), were approved by the Compensation Committee and are in accordance with N", "url": "https://www.businesswire.com/news/home/20260630221318/en/Sarepta-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4", "source_name": "Business Wire", "published_at": "2026-07-01T06:39:04", "published_display": "01 Jul 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Accepts Sarepta's sNDAs for Casimersen and Golodirsen for Duchenne Muscular Dystrophy", "summary": "The FDA has accepted Sarepta Therapeutics' supplemental new drug applications (sNDAs) for casimersen (Amondys 45) and golodirsen (Vyondys 53) for Duchenne muscular dystrophy (DMD), setting a PDUFA target action date of February 28, 2027. These submissions aim to convert the exist", "url": "https://www.neurologylive.com/view/fda-accepts-sarepta-sndas-casimersen-golodirsen-dmd", "source_name": "NeurologyLive", "published_at": "2026-07-01T03:39:04", "published_display": "01 Jul 2026 03:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45\u00ae and VYONDYS 53\u00ae", "summary": "Sarepta Therapeutics announced that the FDA has accepted supplemental New Drug Applications (sNDAs) for AMONDYS 45\u00ae and VYONDYS 53\u00ae for Duchenne muscular dystrophy (DMD), with a PDUFA target action date of February 28, 2027. These sNDAs aim to convert the accelerated approvals of", "url": "https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-fda-acceptance-sndas-amondys-45r-and-vyondys", "source_name": "Sarepta Therapeutics", "published_at": "2026-06-30T18:39:51", "published_display": "30 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Accepts Sarepta's Applications for Full Approval of Two DMD Treatments", "summary": "The FDA has accepted Sarepta's applications for Amondys 45 and Vyondys 53, setting a target decision date of February 28, 2027, for full approval of these Duchenne muscular dystrophy (DMD) treatments. The applications are supported by clinical and real-world data showing positive", "url": "https://intellectia.ai/news/stock/fda-accepts-sareptas-applications-for-full-approval-of-two-dmd-treatments", "source_name": "Intellectia AI", "published_at": "2026-06-30T17:11:20", "published_display": "30 Jun 2026 17:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA to review Sarepta\u2019s Duchenne drugs, with decision due Feb. 28, 2027", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQZDVjR000em1YQjlrQnhfSWl6VXNpbWYzMkEyeVdOUXlVZkpLVklMOGtpOVgtc0dvTTB5b2hEY1A5UGEzTndJckM2NlJBeXBzTkludUVlSmR5R3dwQWtxMUxtWHNuTmFBZXE1em5ZTUFVUzlQT0ZzcG1hUGZadmxoYU5LNzhfa1FJNm1qRWRCSHk4aVZ3bGlVbVBvUUd5NXlaTVhEeGN5cGxiUV80ZldLci1PWm9oZEZs?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SRPT Stock Climbs After Sarepta Seeks Permanent FDA Nod For Two Duchenne Therapies", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOR3hMNjFwMmxxQ0lwNzdZY19OS1pSUmtpV2tOOE9TX0xOLTJRbTJiZDkwQ3JFUHFNX0JMaU8yOFRPOUNvdHF5NUhxTWRxRHEwZVRLWk5MY0d0alllbGdKNG55dW1xSUxUb2pSdWwycWhlSGNZSWdobmQybDNOdDNvS1d6X0JnUDRWaG5XVkVsMXlxV0hZZl84?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring a Potential 43.7% Upside in the Biotech Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxPeGtMV3dsYmlHdnZYTnBPcUdBb0l0Q3hnZy1nNEl1UklOX3ZiMzcxd3NGOElOcF9ybEttYldnOHpCOW5qMExmc25XYkdhTU9UNlBNTExiMm5YdWJpS2o2cXpMSTNGcndtT1B3ekVwOVg4TmNtU0ViVFJHRXN1OWhVbENNZ0ZTcHJrTnFNOUdNTjlselA3Zld4TUhjQWIyUU1tYno4cFJOMFhhWWhBRS1MeGw3UDFHYV9Ea1JZZDZDcU1SYVctYlp1a3RZRVRJVVgzVWlISzNkT2hjU1duMERhU2xUREFCZw?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQWTEzWXI2NXhNMFlmREM0Yzl0elQ0WWtuTG1uV0ZWUnlaMG9Feno0OVg3cGV2WXZqZ0U1NVpFWTZobGdZU01GUF8tU01fZWVLUDFRSXlxV0oxamdIbEFIbTM1cDVxNjFKQkM1RmZjMWVlVW9ITFBVYmIyOENmMG5Xd0ZnYm1DZkMxcHN0c21BaDNLTUF2b0VDenEtU05oOHk4MmVQMTRn?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring a 23% Potential Upside in the Biotech Arena", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxQRmZDQzFrS0t1SGk1OGx0SF8xZVhzSEIyVEtyRklrYjdrWHpXbGYzalV4UFZZbzNnWmkyaEppWl9uRDJIcUFWLWRJWkJqQ2RkeUp3cWZUYkxoU2Y2MWVqVnplakpNdXhUNXhMQmgxeTV3bjY1N3d0cUhFbGVOcEl5RVZZMV96Q3B4VVVQUVFVbzEycWNFTUEzUHhORHlZM2NIZ2pfMU5weTdsRkZJMmFlTUVwb1pSUnEycnYxWlpjMF9Pb0VndDNQMGMtemEtUjdxNzIxa1lvdi04MUVNOTlhaWdR?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "In Solid Cash Position, Sarepta Therapeutics Inc (SRPT) Outlines 2026 Priorities", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQdTh2S3pWR3ZmN3YyN0twbGhqb2tROXV6REtUN21xODh4MWhNR0pEb3VKb1N6VE9UUkprN3lQb052OGl2ZE5FdUdsMEtlWkIyRE1wTm1OR1RabkZYQm10TExvTFcxMk5iaUU2WlhkaFIyekdna2pRRGpGejBHZjA2MkV3Zkc3bXpFbHR4MFpSem5tZ0dvc0liSVZ6Y2xxMU9HREtwU2Y3N0pwSTQyWFE?oc=5", "source_name": "Market source", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQZVBVbDFVMnJpUlo4NVN3SDVmQ01pMEE2NktHbVdhS0dUenotaUptTnJnOWF2dXhuUm5hdHozbHFCM1AwWG84LVA3OElZLW1SVC1JWWpMT2I3WGtESmN2WlZncUY4TlhPR1U2eDNFa1dURlVVWlBRUHVWNHl0ZzJHdDNmY2VFTU9OX2s2aFFEa1NIZDg1TFVDQ1pRQjFESWlXVnJWbGJsUjRLckRiV1Zr?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Elevidys Matters For Sarepta Therapeutics Inc (SRPT) Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOR3hMTUpuOVg4X3dmZ056QmVEdko1SkUxbGJIcE00ZHBBNUpjN2JYSGxIOV9HT3lfLWotckZLRTVYUEdaT29fMFRZU3BtbjF3ZFY3bWY0emJYSkJHLUh6STZzV0VXSXBfMTJoSDJuVTIyMlJDdEZpQmZmdGdfUXlqM1NyWlhuMFY5Xzk5YUR6eXFzRF9KU0ZoeWNMMjRQZmR5NFhpZTNtMTVma21WbWpF?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Solid Earnings, But It Is Not All Good News", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Sarepta Therapeutics (SRPT) A Potential Opportunity After Sharp Multi\u2011Year Share Price Declines?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPVlY0ZUozMVB5WWlYaXllUjEyX1J5eGsxVnFXNUxaZG0xNGUycy1OeE12UjJhdVQzREc5RFdoVnRvd3VCUzNrUkxFUHJ3ZC03MGJHSExMSF9HSDJTaXRaMWhROXhXTzlCdlFBYm8xZXRxekdoWDhWYTNLa1dNVjNhWi1xY1NfNnp1NFlhVmx2dFpHMWkwWXZvMGdrQ01uejFpaGEwWk9Fdnk2SVNEcGN4VkpONWtDTl9ybm5vbzJRajQtNm5pOTczZDB4a2o?oc=5", "source_name": "Sarepta Therapeutics", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[10-Q] Sarepta Therapeutics, Inc. Quarterly Earnings Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOQkR4Nlp0a2xyR0ZkQXRtNl9wUWpieEd3dHFPR3l2cV9ldmphaTd1eUhvMnZEYS1WcWxGRlRkTWRKVTJJbWJSS0dTaHMxYVlDbkQwVWhkdVVGVVRFMGgzYnl2RDZUTFZvWXNRNUp3Y2FsbGJMc0x0RUxCN29rNno3b0V4QU9yYk04NWpwaE95cUMyTmVQVkpJMjREcDNNRktzbHZFVk9BSUI3LTFkeGFsNTNhYjR1Z1Bx?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNaS1Rb0lPUi1jNlpkSGpWd1g1V3FYN05mclpZamY3RDFNTGxKZG5wTVdQdl9TaGI0aXBQVVEzY05MLVRYSmk0ZDAwaGx5YmpaMmNPY0xQNHBoSTNzdjJwTXRxeXZEMkp6MHhvLTFyS3pvWDdFRHIzWmRnME9UX3hGLXBSUC1QaEpvUFRmNXhxY01IeEE3Wm1GZ1NKekw2STVQ?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQdFhHNUg2SkVFMGhReXZRZ0gtemdWTGVpTWJ0aEdrRFdJbGFHSnRlZFJ5T1J6V25ZWDdFSV9uMFZMQjFfRXBfN0dscWtQZHA3NDF4b0xFeGJMVTNnTy1KNFZqckMzTUlKc0VXeFVhQllaeWduS25GWDNiNGV6dW81Y1JmQkp2U0FRMnRLVlp6NHd4My1TNno5bkdpdm00VlA5Z3VSMmxqaS00TGdVOEZYVDFXQ3M1UmlpVmlPdDR3Q1dWMnltaXhwRFBBN2xfVUJt?oc=5", "source_name": "Sarepta Therapeutics", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics (SRPT) Q4 Loss Deepens And Tests Bullish Profitability Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOaTdSV3g3Mk5TU1g5SzNKUk1kTnRLRHJmRlVRVS0ycWJuZktLRkZCbU4xa1dnTUlqZHV4ekZISHFxU0dJdFlkUUhJMlZ6LVJqdlJCbFltT0tXMk1VVHBmNVgzZDRNTC1WZVBRSWJGQzRmN0RtU0sxUC0wdzhNZTFCdHdUOVRwSXZ5UmtvOS1xb0xVM1pqblJCRTdjSWZxdlZtSkhqUjBwOXpxWGhkMm1HTk1iTzljdUs3bmxnTzI4bTZoWGtRTFBhSWM0SUtFT1Q2dDNB?oc=5", "source_name": "Sarepta Therapeutics", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues Despite A 35% Share Price Rise", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-04T08:00:00+00:00", "published_display": "04 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta stock ticks up as FDA finalises tighter Elevidys label", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBGcDhsMmJBRVZVbW4xZlhiejBxcTBEUVZlRWJVTGNUQ1Y3WjRHaWxxRFdYeVdHWExJWnAtWGk2UHc1NjRxUmtPX1FUTVVhci1rZldz?oc=5", "source_name": "FirstWord PHARMA", "published_at": "2025-11-14T08:00:00+00:00", "published_display": "14 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 109, "total_relevant": 69, "sentiment_summary": {"positive": 19, "negative": 6, "neutral": 44, "score": 54, "total": 69, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 18.5, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 11.41, "count": 23}, {"event": "analyst", "label": "Analyst action", "weight": 4.4, "count": 8}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 19, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 18.95, "latest_week": "2026-07-10", "one_week_move": -1.7, "four_week_move": 23.8, "twelve_week_move": -12.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.088778, "market_dynamics_buy_signal": false, "relative_strength": -15.89479, "fair_value_gap": -75.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 48.8572, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.7% over one week, +23.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "TradingView", "count": 8}, {"label": "simplywall.st", "count": 6}, {"label": "Stocktwits", "count": 4}, {"label": "Sarepta Therapeutics", "count": 4}, {"label": "Simply Wall Street", "count": 3}, {"label": "DirectorsTalk Interviews", "count": 3}, {"label": "Stock Titan", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 60}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 23}, {"label": "Analyst action", "count": 8}, {"label": "Regulatory and legal", "count": 4}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "60", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.7% over one week, +23.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "SRPT Stock Clocks Highest Daily Gain In Nearly 8 Years After Rare Muscle Disorders Study Data But Wall Street's Not Wholly Convinced"}], "updated_at": "2026-07-17T13:09:10.521965+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}